DBV Technologies Stock: +28.87% at Opening, Boosted by VITESSE Study Results
DBV Technologies announced on Tuesday the positive results of its phase 3 VITESSE study on its Viaskin Peanut patch for children with peanut allergies. The trial met its primary efficacy endpoint, with 46.6% of treated children responding to the treatment after 12 months, compared to 14.8% in the placebo group. This 31.8 percentage point difference significantly exceeds the minimum threshold required by the FDA.
Significant Market Reaction to Positive Study Results
At the opening this Wednesday, DBV Technologies showed a marked increase of 28.87%, trading at €3.95 compared to €3.07 the day before. This dynamic is part of a well-established trend over several weeks: the stock has accumulated gains of 33.9% over seven days and 142.3% over three months. Over twelve months, the rebound reaches 525%, far beyond the performance of the CAC 40, which has only recorded a progression of 10.57%. The trading reflects a market interest in this announcement, with a volume representing 1.06% of the circulating capital, indicating active participation without reaching exceptional levels. The stock is now trading well above its 50-day moving average, set at €2.61, confirming a short-term upward structural movement.
Technical Outlook for DBV Technologies Stock
Technically, the stock is positioned just below its resistance at €3.45, a level that had previously hindered progressions. The Relative Strength Index (RSI), established at 68, signals a moderate overbought zone where buying tensions dominate, without ruling out further short-term gains. The MACD, a momentum indicator, displays a bullish configuration with a line at 0.19 and a signal at 0.10, the histogram showing 0.09, indicating a strengthening of buying flows. The monthly volatility is set at 28.43%, reflecting significant swings for a biotechnological value. With a beta of 0.50, DBV Technologies shows moderate sensitivity to market movements, partly explaining its outperformance compared to the Paris index.
